Last reviewed · How we verify

NCT05505279

Ventilatory Effects of THRIVE During EBUS

Completed Phase 3 Last updated 15 August 2024
What this trial tests

Phase 3 trial testing THRIVE (High Flow Nasal Cannula) in Hypercapnia in 20 participants. Completed in 8 August 2024.

Timeline
5 October 2022
Primary endpoint
8 August 2024
8 August 2024

Quick facts

Lead sponsorRijnstate Hospital
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingtriple
Primary purposesupportive care
Enrollment20
Start date5 October 2022
Primary completion8 August 2024
Estimated completion8 August 2024
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Rijnstate Hospital

Who can join

18 and older, any sex, with Hypercapnia or Sedation Complication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

High flow nasal cannula (HFNC) is used in interventional procedures to prevent hypoxia during sedation. In patients with a patent airway, HFNC reduces dead space ventilation as well. It is unknown if dead space ventilation is also reduced by HFNC in an EndoBroncheal UltraSound procedure, in which the airway is partially blocked by the endoscope. Especially in patients with Chronic Obstructive Pulmonary Disease (COPD) the partial blocking of the airway may reduce ventilation. If HFNC is able to reduce dead space during an EBUS-procedure, it may facilitate CO2 clearance, which may lead to a reduction in work of breathing. This study aims to investigate if HFNC reduces dead space ventilation in patients undergoing an EBUS-procedure and if this is flow-dependent. A randomized, double-blinded, cross-over study is designed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypercapnia

Currently open trials in the same condition.

Other Rijnstate Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05505279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing